# **BIOGEN IDEC INC.**

ISIN: US09062X1037 WKN: 09062X103 Asset Class: Stock



### **Company Profile**

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

# Financial figures, Fiscal year: from 01.01. to 31.12.

	20	21	20	20	20	19
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	7,856,500,000		6,887,100,000		8,381,800,000	
Common stock capital		100,000		100,000		100,000
Fixed assets	16,020,800,000		17,731,800,000		18,852,500,000	
Equity capital of a company		10,959,700,000		10,686,100,000		13,339,100,000
Cash and cash equivalents	2,261,400,000		1,331,200,000		2,913,700,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		4,298,200,000		3,742,200,000		4,863,800,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		8,619,400,000		10,190,600,000		9,031,400,000
Different income		-		-		-
Other liabilities		1,320,500,000		1,329,600,000		1,348,900,000
Total assets	23,877,300,000	23,877,300,000	24,618,900,000	24,618,900,000	27,234,300,000	27,234,300,000

#### **Balance notes**

	2021	2020	2019
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	9,610	9,100	7,400
Equity ratio	46.17%	43.35%	48.96%
Debt-equity ratio	116.61%	130.69%	104.23%

## **Others**

	2021	2020	2019
Tax Expense Rate	3.01%	19.66%	16.25%

# **BIOGEN IDEC INC.**

ISIN: US09062X1037 WKN: 09062X103 Asset Class: Stock

Income statement			
	2021	2020	2019
Turnover	10,402,400,000	12,356,000,000	12,714,000,000
Net income	1,556,100,000	4,000,600,000	5,888,500,000
EBIT	1,920,466,080	5,025,319,200	6,890,280,480
Operating income before taxes	1,745,200,000	5,047,500,000	7,125,900,000
Cash Flow	3,639,900,000	4,229,800,000	7,078,600,000
Net interest income	-278,900,000	-249,000,000	-136,200,000
Research and development expenses	2,265,900,000	3,789,000,000	2,090,000,000
Income taxes	52,500,000	992,300,000	1,158,000,000
Result from investments in subsidaries, associates and other	34,900,000	5,300,000	-79,400,000
Revenues per employee	1,027,034	1,288,283	1,630,141

# **Board of Directors**

Members of Management Board		
Stelios Papadopoulos	Chairman of Board of Directors	
Alexander Denner	Member of Board of Directors	
Eric Rowinsky	Member of Board of Directors	
Maria Freire	Member of Board of Directors	
Richard Mulligan	Member of Board of Directors	
Stephen Sherwin	Member of Board of Directors	
Caroline Dorsa	Member of Board of Directors	
Jesus Mantas	Member of Board of Directors	
William Hawkins	Member of Board of Directors	
William Jones	Member of Board of Directors	
Christopher Viehbacher	Chairman of Managing Board	
Alphonse Galdes	Member of Executive Committee	
Anabella Villalobos	Member of Executive Committee	
Ginger Gregory	Member of Executive Committee	
Jake Elkins	Member of Executive Committee	
Mahalakshmi Radhakrishnan	Member of Executive Committee	
Priya Singhal	Member of Executive Committee	
Rohin Mhatre	Member of Executive Committee	
Michael Dambach	Member of Executive Committee	
Michael Hencke	Member of Executive Committee	
Michael McDonnell	Member of Executive Committee	
Rachid Izzar	Member of Executive Committee	
Robert Kilo	Member of Executive Committee	
Robin Kramer	Member of Executive Committee	
Susan Alexander	Member of Executive Committee	